Anthropic says it wants to develop drugs in-house

The Verge reports that Anthropic used its Claude Science launch to say it wants to develop drugs of its own. Head of life sciences Eric Kauderer-Abrams said the company will focus on neglected diseases, placing Anthropic in the unusual position of both selling AI tools to drugmakers and potentially becoming a drug developer. Experts told The Verge that AI can help across drug discovery, but real-world experiments, clinical trials, and regulatory approval remain long and expensive.

Key details: Anthropic announced Claude Science as an AI workbench for scientists, The company says it wants to discover treatments for neglected diseases, No AI-designed drug has yet received FDA approval.

Why it matters: Frontier model labs are starting to move from selling science tooling into directly competing in scientific and biomedical markets.